Read by QxMD icon Read

Subcutaneous heparin every 8 hours vs 12 hours

Steven W Boyce, Dennis F Bandyk, John R Bartholomew, James N Frame, Lawrence Rice
Because of an extreme risk for thromboemboli, patients with suspected heparin-induced thrombocytopenia (HIT) require immediate initiation of an alternative anticoagulant. The only therapies approved by the Food and Drug Administration require intravenous infusion of expensive direct thrombin inhibitors. This prospective, randomized, open-label, exploratory study compared the clinical and economic utility of subcutaneous desirudin vs argatroban, the most frequently used agent for suspected or immunologically confirmed HIT, with or without thrombosis...
January 2011: American Journal of Therapeutics
José Victoria Campos, Ursulo Juárez Herrera, Martín Rosas Peralta, Eulo Lupi Herrera, Héctor González Pacheco, Carlos Martínez Sánchez, Eduardo Chuquiure Valenzuela, Gerardo Vieyra Herrera, Carlos Cardozo Zepeda, Carlos Barrera Sánchez, Jesús Reyes Corona, Evelyn Cortina de la Rosa, Aurora de la Peña Díaz, Raúl Izaguirre Avila, Andrés de la Peña Fernández
UNLABELLED: In this prospective, randomized and controlled study, we compare complications in 2 groups of patients: group 1, enoxaparin 0.8 mg/kg, subcutaneous every 12 hours during 5 days, and group 2, intravenous unfractionated heparin during 5 days, by infusion treated to activate partial tromboplastin time 1.5-2 the upper limit of normal. Blood samples were obtained at 4, 12, 24 hours and at day 5 of treatment, to measure anti-Xa levels, and also, evaluated end points at 30 days, between groups...
July 2002: Archivos de Cardiología de México
R M Balen, C A Marra, P J Zed, M Cohen, L Frighetto
OBJECTIVE: To determine the cost effectiveness of enoxaparin therapy versus unfractionated heparin (UFH) therapy for patients with unstable coronary artery disease from the perspective of a Canadian hospital. DESIGN: A predictive decision analysis model using published clinical and economic evaluations and costs of medical care in Canada. PATIENTS: A hypothetical cohort of patients presenting to hospital with unstable angina or non-Q-wave myocardial infarction as defined by the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial...
November 1999: PharmacoEconomics
C M Samama, F Gigou, P Ill
Several clinical trials have been conducted to study the role of low-molecular-weight heparin (LMWH) in the prevention and treatment of venous thrombosis. In contrast, there have been few studies investigating LMWH in the prophylaxis in arterial thrombosis. After informed consent and institutional approval were obtained, 201 consecutive patients scheduled for femorodistal reconstructive surgery under general anesthesia were enrolled in an open randomized multicenter (n = 14) study (from November 1990 to November 1992)...
1995: Annals of Vascular Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"